Full-Time
Associate Director, Clinical Research
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
Compensation Overview
$137k - $235.8k/yr
Irvine, CA, USA
Remote
Remote within the United States, with approximately 20–25% travel.
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- A minimum of a Bachelor's Degree, preferably in Life Science, Physical Science, Nursing, or Biological Science.
- A minimum of 8 years of related scientific or technical experience, including a leadership or management role within Clinical Research.
- Significant previous experience in clinical project leadership across multiple studies or programs.
- Experience working with cross-functional teams.
- Experience with budget planning, tracking, and control.
- Deep expertise in clinical research science and processes, product development processes, team dynamics, the healthcare market environment, clinical trends, and global clinical trial regulations.
- Ability to lead cross-functional teams and provide scientific clinical research input across New Product Development and Life-Cycle Management projects, including complex or transformational projects.
- A proven track record of delivering clinical programs in a clinical or surgical research setting on time, within budget, and in compliance with standard operating procedures and regulations.
- Strong presentation and technical writing skills.
- Strong written and oral English communication skills.
- Comprehensive understanding of clinical trial regulations across multiple regions.
- Ability to collaborate across different functional areas within Clinical Research and Development to ensure alignment with governance processes and business objectives.
- Ability to lead teams to deliver critical milestones, including complex projects.
- Advanced technical writing skills.
- Strong project management skills with the ability to handle multiple projects.
- Strong people management skills.
- Effective management of project budget processes.
- Ability to influence, shape, and lead without direct reporting authority.
- Lead a team of clinical research professionals to manage clinical trials and deliver evidence generation and evidence dissemination strategies for multiple or complex projects.
- Execute Clinical Research and Development activities for multiple or complex projects.
- Manage the clinical team's interface and collaboration with key opinion leaders, investigators, institutional review boards or ethics committees, regulatory agencies, contractors, vendors, societies, associations, and company personnel.
- Provide input on and execute the delivery of Global Evidence Generation Strategies and Evidence Dissemination Strategies to support New Product Development and Life-Cycle Management.
- Foster collaborative relationships with Clinical Research and Development and cross-functional partners to ensure alignment.
- Coordinate input and alignment from regional medical doctor Clinical Research and Development leads and other countries or regions in developing evidence strategies.
- Lead study design to develop appropriate clinical trials to meet clinical evidence needs.
- Foster working relationships with external stakeholders.
- Partner with internal stakeholders to disseminate clinical data and evidence in value briefs and technical summaries for market access and reimbursement.
- Deliver assigned clinical programs through effective internal and external partnerships, on time, within budget, and in compliance with regulations and standard operating procedures.
- Maintain accurate, up-to-date project knowledge for key stakeholders.
- Monitor assigned project budgets for adherence to globally defined business plans.
- Lead clinical scientific discussions with regulatory agencies and notified bodies to support clinical and regulatory strategy, including proposed clinical investigations and review of clinical evidence for marketing authorization and line extensions.
- Serve as the clinical representative on a New Product Development team.
- Develop Post-Market Clinical Follow-up Plans and Reports.
- Review promotional materials for fair balance, accuracy in clinical claims, and messaging.
- Manage and mentor resources assigned to designated clinical studies to provide quality deliverables and maintain efficiency.
- Provide performance feedback to direct reports and coach and assist with their development.
- Communicate business-related issues or opportunities to the next management level.
- Ensure compliance with company guidelines and applicable federal, state, local, and company regulations, policies, and procedures.
- Ensure subordinates follow company Health, Safety, and Environmental guidelines when supervising or managing staff.
- Perform other assigned duties as needed.
- Relevant industry certifications such as Certified Clinical Research Associate, Certified Clinical Research Coordinator, Certified Clinical Research Professional, Regulatory Affairs Certification, Certified Diabetes Educator, Good Clinical Practice, International Organization for Standardization 14155, or Medical Device Regulation experience.
- Clinical or medical background.
- Medical device experience.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
- TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
- The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.
What critics are saying
- Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
- The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
- A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.
What makes Johnson & Johnson unique
- J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
- TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
- TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.
Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.